Compare XHR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XHR | GPCR |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2023 |
| Metric | XHR | GPCR |
|---|---|---|
| Price | $14.67 | $67.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $14.14 | ★ $94.90 |
| AVG Volume (30 Days) | 776.2K | ★ 2.5M |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ 139.32 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,074,772,000.00 | N/A |
| Revenue This Year | $4.52 | N/A |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | $26.20 | ★ N/A |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $8.55 | $13.22 |
| 52 Week High | $16.27 | $94.90 |
| Indicator | XHR | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.75 | 78.11 |
| Support Level | $13.39 | $65.02 |
| Resistance Level | $14.24 | $72.39 |
| Average True Range (ATR) | 0.30 | 6.45 |
| MACD | 0.07 | 3.66 |
| Stochastic Oscillator | 96.20 | 56.86 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other. Xenia's revenue is divided between room, food and beverage, and other. The firm's customer groups include transient business, group business, and contract business.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.